The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessAbstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Items 901–1,000 of 1,000
Vogel, R., Al‐Daccak, R., Drews, O., Alonzeau, J., Mester, G., Charron, D. J., Stevanović, S., & Mallet, J. J. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.3 · Cited by 8
Corre, G., Dessainte, M., Marteau, J., Dalle, B., Fenard, D., & Galy, A. H. M. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.166 · Cited by 7
Self-citationŠenigl, F., Miklík, D., Auxt, M., & Hejnar, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx889 · Cited by 9
“An example of the benign clonal expansion of a lentiviral vector integrated into the HMGA2 gene was documented in a study, which successfully implemented -thalassemia gene therapy (29).”
BackgroundHa, T.-C., Stahlhut, M., Rothe, M., Paul, G., Dziadek, V., Morgan, M. A., Brugman, M. H., Fehse, B., Kustikova, O. S., Schambach, A., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.344 · Cited by 7
“8 It was demonstrated that sequences of common insertion sites (CIS) recovered from RIM-induced dominant hematopoietic clones overlapped with known stem cell regulators 7 and nonmalignant clonal dominance associated with vector integration site was observed in lentiviral gene therapy.”
Ethical issues in neurogenetic disorders
Kang, P. B. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53501-6.00022-6 · Cited by 7
Kansal, R. (2025) · Genes · doi:10.3390/genes16111367 · Cited by 6
Fischer, A., Ehrlich, A., Plotkin, Y., Ouyang, Y., Asulin, K., Ioannidis, K., Fan, C., Nahmias, Y., & Willner, I. (2023) · Angewandte Chemie · doi:10.1002/ange.202311590 · Cited by 6
Self-citationGlobal Trends on β-Thalassemia Research Over 10 Years: A Bibliometric Analysis
Lv, A., Li, J., Chen, M., Wang, W., Xu, L., & Huang, H. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s479493 · Cited by 8
“39 Subsequent clinical trials, such as HGB-204 and HGB-205 sponsored by Bluebird Bio, utilized an improved vector called LentiGlobin BB305.”
MethodOvercoming the Silencing of Doxycycline-Inducible Promoters in hiPSC-derived Cardiomyocytes
Guichardaz, M., Bottini, S., Balmas, E., & Bertero, A. (2024) · Open Research Europe · doi:10.12688/openreseurope.19024.1 · Cited by 8
“We employed a minimal 0.7 kb version of the A2UCOE, lacking the HNRPA2B1 promoter, to maintain an open chromatin state without introducing aberrant splicing events associated with larger UCOE constructs 20,22 .”
InfluentialYannaki, E., Psatha, N., Παπαδοπούλου, Α., Athanasopoulos, T., Gravanis, A., Roubelakis, M. G., Tsirigotis, P. D., Anagnostopoulos, Α., Anagnou, N. P., & Vassilopoulos, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.196 · Cited by 6
“35 Importantly, the HbAT87Q fraction was derived by a benign, although dominant, clone at an integration site close to the HMGA2 gene.”
Moiseenko, A., Sinadinos, A., Sergijenko, A., Pineault, K. M., Saleh, A., Nekola, K., Strang, N., Eleftheraki, A. G., Boyd, A., Davies, J. C., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.01683-2023 · Cited by 8
Fostering a healthier generation of children with sickle cell disease through advancements in care
Franco, E., Nimura, C. A., & McGann, P. T. (2024) · Pediatric Research · doi:10.1038/s41390-024-03566-w · Cited by 6
Regenerative Medicine: Challenges and Perspectives for Successful Therapies
Viswanathan, S., & Joshi, C. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_290 · Cited by 7
“Over the past decade a number of clinical studies have provided proof of concept that genetically modified hematopoietic stem and progenitor cells can be used to treat metabolic disorders and monogenic diseases (Cavazzana-Calvo et al. 2010; Cartier et al. 2009).”
BackgroundTranscriptionally regulated and nontoxic delivery of the hyperactive Sleeping Beauty Transposase
Cocchiarella, F., Latella, M. C., Basile, V., Miselli, F., Galla, M., Imbriano, C., & Recchia, A. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.38 · Cited by 6
Zhao, H. F., Abraham, A., Kim, Y., Wang, Y., Pestina, T. I., Zhan, J., Humphries, R. K., Nienhuis, A. W., & Persons, D. A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.019 · Cited by 6
Aziz, N., Khan, M. N., Haq, F. U., Ahmed, F., Ali, A., El-Seedi, H. R., & Musharraf, S. G. (2020) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2020.10.024 · Cited by 6
Brown, G., Hughes, P., Ceredig, R., & Michell, R. H. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.10.010 · Cited by 6
“For example, in a human -thalassaemia trial using HSCs into which a vector with a corrective -globin gene had been integrated, expansion of the modified cells was myeloid-biased; the progeny included multipotent long-term haematopoietic cells (LTC-IC), erythroblasts, granulocytes and monocytes, but not lymphocytes [80…”
MethodIdentifying targets for gene therapy of β-globin disorders using quantitative modeling approach
Bashirov, R., & Mehraei, M. (2017) · Information Sciences · doi:10.1016/j.ins.2017.02.053 · Cited by 6
Papapetrou, E. P. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_9 · Cited by 7
Gene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 7
Pressing diseases that represent promising targets for gene therapy.
Beitelshees, M., Hill, A. B., Rostami, P., Jones, C. H., & Pfeifer, B. A. (2017) · PubMed · Cited by 12
Engineering precision therapies: lessons and motivations from the clinic
Xie, M., Viviani, M., & Fussenegger, M. (2020) · Synthetic Biology · doi:10.1093/synbio/ysaa024 · Cited by 11
“For example, the ATMP therapy Zynteglo is based on autologous CD34þ cells transduced with a lentiviral vector harboring the bA-T87Q-globin gene and is approved for patients with transfusion-dependent b-thalassemia (86, 87) (Supplementary Table S1).”
Gan, Q. F., Foo, C. N., Leong, P. P., & Cheong, S. K. (2021) · International Journal of Therapy and Rehabilitation · doi:10.12968/ijtr.2019.0119 · Cited by 6
Liskovykh, M. A., Larionov, V., & Kouprina, N. (2021) · Current Protocols · doi:10.1002/cpz1.236 · Cited by 6
“In addition, the use of viral vectors may induce undesired immunological responses and may occasionally integrate into the host genome, which can result in detrimental insertional mutagenesis and gene silencing (Cavazzana-Calvo et al., 2010; Odom et al., 2007).”
BackgroundReactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia
Ma, S., Gao, X.-X., Zhou, G., Zhang, H., Yang, J.-M., Wang, W., Song, X., Chen, H., & Lu, D. (2022) · Gene · doi:10.1016/j.gene.2022.146289 · Cited by 7
Guerra, A., Musallam, K. M., Taher, A. T., & Rivella, S. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.11.002 · Cited by 7
Luchetti, A., Filareto, A., Sanchez, M., Ferraguti, G., Lucarelli, M., Novelli, G., Sangiuolo, F. C., & Malgieri, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030851 · Cited by 6
Milestones in the History of Hemoglobin Research (In Memory of Professor Titus H.J. Huisman)
Thein, S. L. (2011) · Hemoglobin · doi:10.3109/03630269.2011.613506 · Cited by 9
The Genetic Aspect of Thalassemia: From Diagnosis to Treatment
Aldemir, Ö. (2018) · InTech eBooks · doi:10.5772/intechopen.76496 · Cited by 6
Hepatic gene therapy using lentiviral vectors: Has safety been established?
Dismuke, D. J., & Samulski, J. R. (2013) · Hepatology · doi:10.1002/hep.26460 · Cited by 6
“Because of these characteristics, a number of clinical trials have used c-RV or LV with promising results.(4-9) Although the early safety measures of these trials were lauded for minimal side effects, enthusiasm for gene therapy was weakened by the development of lymphoproliferative disorders in several of the patient…”
BackgroundParoxysmal Nocturnal Hemoglobinuria
Kinoshita, T. (2012) · Wiley eBooks · doi:10.1002/9780470015902.a0005538.pub2 · Cited by 6
A plethora of gene therapies for hemoglobinopathies
Dunbar, C. E. (2021) · Nature Medicine · doi:10.1038/s41591-021-01235-7 · Cited by 6
The promise of in vivo HSC prime editing
Sweeney, C. L., & Ravin, S. S. D. (2023) · Blood · doi:10.1182/blood.2023019922 · Cited by 6
Development of Gene Transfer Technology
Mulligan, R. C. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2543 · Cited by 5
Ren, J., & Stroncek, D. F. (2016) · Blood · doi:10.1182/blood-2016-09-736983 · Cited by 5
Koniali, L., Flouri, C., Kostopoulou, M. I., Papaioannou, N. Y., Papasavva, P. L., Naiisseh, B., Stephanou, C., Demetriadou, A., Sitarou, M., Christou, S., et al. (2023) · Cells · doi:10.3390/cells12242848 · Cited by 5
“…(LV) transfer of β -globin ( HBB ) or HBB -like globin genes into hematopoietic stem and progenitor cells (HSPCs) represents a promising curative therapeutic approach for transfusion-dependent β -thalassemia patients who lack a suitable human leukocyte antigen (HLA)-matched sibling donor [3–6].”
BackgroundHu, P., Hao, Y., Tang, W. H., Diering, G. H., Zou, F., & Kafri, T. (2025) · Viruses · doi:10.3390/v17020276 · Cited by 5
“Cavazzana-Calvo et al. [9] reported a loss of polyclonality in a successful gene therapy protocol for b-thalassemia.”
Modeling integration site data for safety assessment with MELISSA
Lin, T., Ceoldo, G., House, K. D., Welty, M., Dang, T. T., Klatt, D., Brendel, C., Murphy, M. P., Cornetta, K. G., & Pellin, D. (2025) · Nature Communications · doi:10.1038/s41467-025-63017-w · Cited by 5
Self-citationIndustry Update: Latest Developments in Stem Cell Research and Regenerative Medicine
Ilić, D. (2010) · Regenerative Medicine · doi:10.2217/rme.10.44 · Cited by 5
Promises and Challenges in Hematopoietic Stem Cell Gene Therapy
Kohlscheen, S., Bonig, H. B., & Modlich, U. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.141 · Cited by 5
Kim, J., Park, M., Baek, G. W., Kim, J.-I., Kwon, E., Kang, B., Kim, J., & Kang, H. J. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.05.004 · Cited by 5
“Two such mechanisms are i) as in the TET2 gene, inactivation of the catalytic domain of tumor suppressor genes by insertional disruption(15) and ii) as in the HMG2A gene, activation via mRNA 30 end substitution that suppresses RNA degradation.(35) In this study, we focused on the certain genomic regions rather than ex…”
BackgroundRegulation for Gene and Cell Therapy Medicinal Products in Europe
Renner, M., Anliker, B., Flory, E., Scherer, J., Schüßler‐Lenz, M., Schweizer, M., & Ivics, Z. (2015) · Springer eBooks · doi:10.1007/978-4-431-55666-4_10 · Cited by 5
Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
Nalla, A. K., & Trobridge, G. D. (2016) · Biomedicines · doi:10.3390/biomedicines4020008 · Cited by 6
Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors
Bii, V. M., & Trobridge, G. D. (2016) · Cancers · doi:10.3390/cancers8110099 · Cited by 5
“syndrome [57,58], adenosine deaminase deficiency (ADA) [59,60], X-linked adrenoleukodystrophy [61,62], X-linked chronic granulomatous [63], β-thalassemia [64], and Wiskott-Aldrich syndrome [65].”
BackgroundAlonso-Ferrero, M. E., van Til, N. P., Bartolović, K., Mata, M. F., Wagemaker, G., MOULDING, D. A., Williams, D. A., Kinnon, C., Waddington, S. N., Milsom, M. D., et al. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.09.003 · Cited by 5
Meng, J., Moore, M., Counsell, J. R., Muntoni, F., Popplewell, L. J., & Morgan, J. E. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.015 · Cited by 6
Thomas, D., & Mostoslavsky, G. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-761-7_29 · Cited by 5
Cord blood transplantation in children with hemoglobinopathies
Strocchio, L., Romano, M., Cefalo, M. G., Vinti, L., Gaspari, S., & Locatelli, F. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1076724 · Cited by 7
“, genetherapy approaches based either on the insertion of a normal b-globin gene carried by a lentiviral vector [47-49], or the introduction of a lentiviral vector carrying a DNA section encoding the human g-globin gene [50,51], or the transgenic activation of endogenous g-globin genes [52,53]) are likely to allow the…”
BackgroundThe Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy forβ-Thalassemia
Drakopoulou, E., Papanikolaou, E., & Anagnou, N. P. (2011) · Stem Cells International · doi:10.4061/2011/987980 · Cited by 6
“Similarly, the 18-year-old patient in the first clinical trial discussed above showed an average of 15% genetically modified HSCs [46], supporting even further the notion that higher percentages of genetically modified HSCs in the case of human and nonhuman primates is not an easy task.”
BackgroundInfluentialPerspectivas da terapia gênica
Costanzi-Strauss, E., & Strauss, B. E. (2015) · Revista de Medicina · doi:10.11606/issn.1679-9836.v94i4p211-222 · Cited by 35
Mehraei, M., Bashirov, R., & Tüzmen, Ş. (2016) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720016500268 · Cited by 7
Therapeutic advances in sickle cell disease in the last decade
Shet, A. S., & Thein, S. L. (2017) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1153_17 · Cited by 5
Microfluidic Approach for Highly Efficient Viral Transduction
Tran, R., & Lam, W. A. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_3 · Cited by 5
Lee, M. Y.-H., Khoury, G., Olshansky, M., Sonza, S., Carter, G. P., McMahon, J. H., Stinear, T. P., Turner, S. J., Lewin, S. R., & Purcell, D. F. J. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.855290 · Cited by 6
“Evidence for this has been shown in the past where clinical trials with lentiviral vectors for correction of genetic disorders resulted in alterations to cell proliferation (Cavazzana-Calvo et al., 2010; Cesana et al., 2012; Moiani et al., 2012; Cesana et al., 2017).”
BackgroundVerhoeyen, E. (2012) · Molecular Therapy · doi:10.1038/mt.2012.97 · Cited by 5
Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease
Falcon, C., Al‐Obaidi, M., & Stasi, A. D. (2017) · Biomedicines · doi:10.3390/biomedicines5020030 · Cited by 7
“Gene-modified HSC infused into patients with monogenic disease [102,103,105,106,110] resulted in leukemia from insertional mutagenesis in up to 70% of patients, and even a higher risk may arise with the use of iPSC.”
BackgroundApplications of Virus Vector–Mediated Gene Therapy in China
Lin, Q., Deng-gao, W., Zhang, Z., & Liu, D. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.238 · Cited by 5
“…rare fatal disorders ( e.g. , X-linked adrenoleukodystrophy, 81 metachromatic leukodystrophy 82 ) and hemoglo-binopathies ( e.g. , b -thalassaemia 83 ) used in other countries, trials using LV or AAV vector–mediated gene therapy to treat these diseases and X-linked severe combined…”
The long road traveled in hematopoietic stem cell gene therapy
Williams, D. A. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.022 · Cited by 5
Zeglinski, K., Montellese, C., Ritchie, M. E., Alhamdoosh, M., Vonarburg, C., Bowden, R. J., Jordi, M., Gouil, Q. A., Aeschimann, F., & Hsu, A. L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.03.569756 · Cited by 5
“This insulator was previously shown to contain a potent cryptic splice acceptor site, which was identified as the cause for clonal dominance in progenitor and myeloid lineages of patients in clinical trials (12)(13).”
BackgroundInfluentialvan Heuvel, Y., & Stitz, J. (2025) · Current Gene Therapy · doi:10.2174/0115665232332412241118063211 · Cited by 6
Kumar, P., Chaudhary, B., Devi, S., Dubey, G., Chatterjee, A., Sharma, D., & Gupta, M. M. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100113 · Cited by 5
Galy, A. H. M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.152 · Cited by 4
“45,48 Thus, careful molecular monitoring remains necessary in patients treated with LVs. In-deed In-deed, LVs have the propensity to integrate inside genes and to induce alternative splicing and aberrant transcripts.”
Wagner, S., Baldow, C., Calabria, A., Rudilosso, L., Gallina, P., Montini, E., Cesana, D., & Glauche, I. (2022) · Nature Communications · doi:10.1038/s41467-022-31292-6 · Cited by 4
Hosuru, R. V., Yang, J., Zhou, Y., Gin, A. L., Hayal, T. B., Hong, S. G., Dunbar, C. E., & Wu, C. (2024) · British Journal of Haematology · doi:10.1111/bjh.19889 · Cited by 4
“expansions and myeloid malignancies in several patients receiving HSPCs transduced with LVs. 10,11 Conditioning regimens as well as potential disease-related underlying HSPC stress and accelerated HSPC ageing due to transplantation have been implicated in addition to possible insertional mutagenesis.”
Nonclinical Studies for Cell-Based Medicines
Sharpe, M. E., Leoni, G., Barry, J., Schutte, R., & Mount, N. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-803115-5.00003-6 · Cited by 4
Future Perspectives for the Treatment of Sickle Cell Anemia
Nottage, K. A., Estepp, J. H., & Hankins, J. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-06713-1_16 · Cited by 4
Gene Therapy for Primary Immunodeficiencies
Cicalese, M. P., & Aiuti, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-77674-3_21 · Cited by 4
Bogert, N. V., Furkel, J., Din, S., Braren, I., Eckstein, V., Müller, J.-A., Uhlmann, L., Katus, H. A., & Konstandin, M. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-70793-6 · Cited by 4
Targeted genome editing for the correction or alleviation of primary Immunodeficiencies
Sipe, C. J., Vázquez, P. N. C., Skeate, J. G., McIvor, R. S., & Moriarity, B. S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.03.001 · Cited by 4
Suleman, S., Alhaque, S., Guo, A. Y., Zhang, H., Payne, A. M., Zahn, M., Fawaz, S., Khalifa, M. S., Jobling, S., Hay, D. C., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00550-9 · Cited by 4
Le diagnostic pré-implantatoire couplé au typage HLA : l’expérience française
Steffann, J., Frydman, N., Burlet, P., Gigarel, N., Hesters, L., Kerbrat, V., Lamazou, F., Münnich, A., & Frydman, R. (2011) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32014-x · Cited by 4
Ariga, T. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.850416 · Cited by 5
Li, L., Torres-Coronado, M., Gu, A., Rao, A., Gardner, A. M., Epps, E. W., González, N., Tran, C.-A., Wu, X., Wang, J., et al. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0010 · Cited by 4
Bonello‐Palot, N., Cérino, M., Joly, P., & Badens, C. (2016) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(16)30130-7 · Cited by 5
An Overview of rAAV Vector Product Development for Gene Therapy
Snyder, R. O. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4939-3228-3_2 · Cited by 4
Baranyi, L., Slepushkin, V., & Dropulić, B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394295-1.00001-9 · Cited by 10
Efficient Transduction and Expansion of Ovine Macrophages for Gene Therapy Implementations
Karponi, G., Kritas, S. K., Petridou, E., & Papanikolaou, E. (2018) · Veterinary Sciences · doi:10.3390/vetsci5020057 · Cited by 4
Regulatory Aspects of ATMP Versus Minimally Manipulated Immune Cells
McGrath, E., & Chabannon, C. (2018) · Springer eBooks · doi:10.1007/978-3-030-02278-5_62 · Cited by 4
Enhanced Transduction of Macaca fascicularis Hematopoietic Cells with Chimeric Lentiviral Vectors
Sii-Felice, K., padilla, J. I. C., Relouzat, F., Cheuzeville, J., Tantawet, S., Maouche, L., Grand, R. L., Leboulch, P., & Payen, E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.179 · Cited by 4
Self-citationGeneration of Murine Induced Pluripotent Stem Cells through Transposon-Mediated Reprogramming
Talluri, T. R., Kumar, D., & Kues, W. A. (2021) · Methods in molecular biology · doi:10.1007/7651_2021_350 · Cited by 4
Avances en terapia génica en humanos: algunos conceptos básicos y un recorrido histórico
Silva, G. E. (2022) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2022.03.001 · Cited by 7
Drépanocytose : le médecin du travail, relais essentiel dans l’information et la prise en charge
Bachir, D., Zemirline, F., Niakaté, A., Cabaret, E., & Galactéros, F. (2015) · Archives des maladies professionnelles et de médecine du travail/Archives des maladies professionnelles et de l'environnement · doi:10.1016/j.admp.2015.04.003 · Cited by 4
Peptides as Promising Non-Viral Vectors for Gene Therapy
Yang, W., & Andrew, J. T. (2011) · InTech eBooks · doi:10.5772/18636 · Cited by 4
Progress in the congenital dyserythropoietic anemias: Juicy but high‐hanging fruits?
Renella, R. (2010) · American Journal of Hematology · doi:10.1002/ajh.21900 · Cited by 4
Nuclease‐stimulated homologous recombination at the human β‐globin gene
Vannocci, T., Kurata, H., de la Fuente, J., Roberts, I. A. G., & Porter, A. C. G. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2751 · Cited by 5
“So far, gene addition therapy for βTM has been described for only one patient where viral vector integration activated of a host gene (HMGA2) previously implicated in tumorigenesis [10].”
BackgroundSellers, S. E., Dumitriu, B., Morgan, M. J., Hughes, W. M., Wu, C. O., Raghavarchari, N., Yang, Y., Uchida, N., Tisdale, J. F., An, D. S., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.168 · Cited by 6
Hemoglobin Gene Therapy for β-Thalassemia
Bank, A. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.08.002 · Cited by 4
Self-citationFinotti, A., Borgatti, M., Bianchi, N., Zuccato, C., Lampronti, I., & Gambari, R. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1135793 · Cited by 6
Ethical Issues of Embryo Genetic Manipulation
Ghafoori, F., Vedadhir, A., & Tehrani, S. G. (2016) · Faṣlnāmah-i akhlāq-i pizishkī./Faṣlnāmah-i akhlāq-i pizishkī. · doi:10.21859/mej-103635 · Cited by 4
Improved biosafety of a lentiviral vector by reducing cellular gene activation
Li, S., He, J., Gao, Y., Fang, Y., Zhang, L., Wang, J., Sun, F., Zhang, F., Zeng, Y., Zeng, F., et al. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3087 · Cited by 4
“Results: By analyzing the EATRT of “pro‐LV” constructs transfected in 293T cells, we observed that the inclusion of the first 400 bp of the chicken β‐globin locus HS4 insulator core sequence oriented in the reverse direction (C–) combined with two copies of the simian virus 40 upstream‐sequence element (U) at the ΔU3…”
BackgroundInfluentialKeohane, E. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-53045-3.00034-9 · Cited by 7
Intratympanic Gene Delivery of Antimicrobial Molecules in Otitis Media
Moon, S. K., & LIM, D. J. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0517-1 · Cited by 4
Retroviruses in Human Gene Therapy
Pedersen, F. S., & Mikkelsen, J. G. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0001002.pub4 · Cited by 4
Progress and Prospects: Advancements in Retroviral Vector Design, Generation, and Application
Mukherjee, S., & Thrasher, A. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.2523 · Cited by 4
“LVs may therefore have an overall safer integration profile, although both exhibit a semirandom pattern of insertion into the human genome, and this type of risk still cannot be ignored (Bushman et al., 2005; Cavazzana-Calvo et al., 2010).”
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
de Oliveira, B. C., Bari, S. M. N., & Melenhorst, J. J. (2025) · Cancers · doi:10.3390/cancers17030383 · Cited by 5
“A second example is the successful treatment of β -thalassemia, which was achieved with a lentiviral vector encoding a β -globin flanked by insulator elements, but concerns regarding long-term safety arose when clonal expansion occurred after integration in the HMGA2 locus [45].”
Advancing ex vivo gene therapy: the role of lentiviral vectors and organizational collaboration
Sano-Fujimoto, Y., Nishida, Y., Kodama, K., Miyashita, S., & Sengoku, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104510 · Cited by 4
Advances in Gene Therapy for Inherited Haemoglobinopathies
Gaspar, A. B., & Gaspar, H. B. (2025) · Hematology Reports · doi:10.3390/hematolrep18010004 · Cited by 4
“It became the first clinical trial to be initiated for gene therapy to treat both transfusion-dependent β -thalassemia (TDT) and SCD [22].”
Yanay, O., Dale, D. C., & Osborne, W. R. A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.045 · Cited by 3
“…vector for gene therapy of human b-thalassemia showed that most of the therapeutic benefit in one adult patient resulted from a dominant, myeloid-biased cell clone, in which the integrated vector caused transcriptional activation of HMGA2 in erythroid cells (Cavazzana-Calvo et al., 2010).”
BackgroundMistry, A., Tanga, S., & Maji, B. (2023) · Springer eBooks · doi:10.1007/978-981-19-8520-1_11 · Cited by 3
Ismail, A. M., Witt, E., Bouwman, T., Clark, W. T., Yates, B., Franco, M., & Fong, S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101294 · Cited by 4
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.